BRPI0607801A2 - método para tratar seletivamente distúrbio mediado pela cox-2 através da administração de gama-tocoferol - Google Patents

método para tratar seletivamente distúrbio mediado pela cox-2 através da administração de gama-tocoferol

Info

Publication number
BRPI0607801A2
BRPI0607801A2 BRPI0607801-0A BRPI0607801A BRPI0607801A2 BR PI0607801 A2 BRPI0607801 A2 BR PI0607801A2 BR PI0607801 A BRPI0607801 A BR PI0607801A BR PI0607801 A2 BRPI0607801 A2 BR PI0607801A2
Authority
BR
Brazil
Prior art keywords
tocopherol
gamma
connective tissue
cox
effective
Prior art date
Application number
BRPI0607801-0A
Other languages
English (en)
Inventor
Peter Hanson
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of BRPI0607801A2 publication Critical patent/BRPI0607801A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MéTODO PARA TRATAR SELETIVAMENTE DISTúRBIO MEDIADO PELA COX-2 ATRAVéS DA ADMINISTRAçãO DE GAMA-TOCOFEROL. A presente invenção se baseia na recente observação da atividade inibitória específica de COX-lI de gama-tocoferol e que pela combinação de gama-tocoferol com precursores de constituintes do tecido conjuntivo, o tecido conjuntivo lesionado ou degenerado, especialmente articulações de pacientes animais, pode ser reparado. O método da invenção para tratar um distúrbio inflamatório de uma articulação compreende administrar ao mamífero uma composição farmacêutica que compreende uma quantidade de gama-tocoferol eficaz na inibição seletiva de ciclooxigenase-2 e pelo menos um composto que eleva a produção de um componente de tecido conjuntivo em uma quantidade eficaz para a promoção da formação de tecido conjuntivo. A invenção também fornece composições farmacêuticas ou veterinárias que compreendem uma preparação de tocoferol que tem pelo menos 50% p/p de gama-tocoferol ou um derivado desse e em uma quantidade eficaz para inibir seletivamente a ciclooxigenase-2 no mamífero receptor e pelo menos um composto que eleva a produção de um componente do tecido conjuntivo.
BRPI0607801-0A 2005-02-22 2006-02-22 método para tratar seletivamente distúrbio mediado pela cox-2 através da administração de gama-tocoferol BRPI0607801A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65519005P 2005-02-22 2005-02-22
PCT/US2006/006046 WO2006091571A2 (en) 2005-02-22 2006-02-22 Methods for selectively treating cox-2 mediated disorders by administering gamma-tocopherol

Publications (1)

Publication Number Publication Date
BRPI0607801A2 true BRPI0607801A2 (pt) 2009-06-13

Family

ID=36927945

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607801-0A BRPI0607801A2 (pt) 2005-02-22 2006-02-22 método para tratar seletivamente distúrbio mediado pela cox-2 através da administração de gama-tocoferol

Country Status (9)

Country Link
US (1) US20070015822A1 (pt)
EP (1) EP1912654A4 (pt)
JP (1) JP2008531569A (pt)
AU (1) AU2006216802B2 (pt)
BR (1) BRPI0607801A2 (pt)
CA (1) CA2598645A1 (pt)
MX (1) MX2007010186A (pt)
WO (1) WO2006091571A2 (pt)
ZA (1) ZA200707106B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7064292B2 (ja) * 2016-07-07 2022-05-10 第一三共ヘルスケア株式会社 ロキソプロフェン又はその塩及びビタミンｅを含有する経口用医薬組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232836A (en) * 1959-08-24 1966-02-01 Pfizer & Co C Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US3371012A (en) * 1964-08-07 1968-02-27 Seikagaku Kogyo Co Ltd Preservative for eye graft material
US4006224A (en) * 1975-09-29 1977-02-01 Lescarden Ltd. Method and agent for treating inflammatory disorders of the gastrointestinal tract
US4486416A (en) * 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
US5364845C1 (en) * 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
US5916565A (en) * 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6242749B1 (en) * 1999-01-30 2001-06-05 Yuri Maishev Ion-beam source with uniform distribution of ion-current density on the surface of an object being treated
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
AU5594700A (en) * 1999-06-01 2000-12-18 Ocean Spray Cranberries, Inc. Cranberry seed oil extract and compositions containing components thereof
US6242362B1 (en) * 1999-08-04 2001-06-05 Taiwan Semiconductor Manufacturing Company Etch process for fabricating a vertical hard mask/conductive pattern profile to improve T-shaped profile for a silicon oxynitride hard mask
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US20020120001A1 (en) * 2000-10-13 2002-08-29 Ashni Naturaceuticals, Inc. Compositions containing tryptamines, cartenoids and tocotrienols and having synergistic antioxidant effect
US20030007982A1 (en) * 2001-04-27 2003-01-09 Peter Surai Novel method for improving antioxidant status of animals consuming feeds contaminated with mycotoxins
US6902739B2 (en) * 2001-07-23 2005-06-07 Nutracea Methods for treating joint inflammation, pain, and loss of mobility
GB0119052D0 (en) * 2001-08-03 2001-09-26 Mars Uk Ltd Foodstuff
CA2456743A1 (en) * 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040102421A1 (en) * 2002-11-21 2004-05-27 Children's Hospital Research Center At Oakland Tocopherol and tocotrienol anti-inflammatory medicaments

Also Published As

Publication number Publication date
JP2008531569A (ja) 2008-08-14
CA2598645A1 (en) 2006-08-31
US20070015822A1 (en) 2007-01-18
AU2006216802A1 (en) 2006-08-31
WO2006091571A3 (en) 2008-01-31
WO2006091571A2 (en) 2006-08-31
AU2006216802B2 (en) 2010-08-05
ZA200707106B (en) 2008-09-25
EP1912654A2 (en) 2008-04-23
EP1912654A4 (en) 2008-09-17
MX2007010186A (es) 2007-11-06

Similar Documents

Publication Publication Date Title
Gomoll et al. Chondrolysis after continuous intra-articular bupivacaine infusion: an experimental model investigating chondrotoxicity in the rabbit shoulder
BR112012002639A2 (pt) métodos e composições para melhorar a saude gastrintestinal
Martinez et al. Pharmacological effects of a C-phycocyanin-based multicomponent nutraceutical in an in-vitro canine chondrocyte model of osteoarthritis
WO2005000331A2 (en) Compositions for the treatment and prevention of degenerative joint disorders
Beale Orthopedic problems in geriatric dogs and cats
Zhou et al. Chondroprotective effects of palmatine on osteoarthritis in vivo and in vitro: A possible mechanism of inhibiting the Wnt/β-catenin and Hedgehog signaling pathways
BRPI0517273A (pt) composição baseada em bactéria probiótica e o uso desta na prevenção e/ou tratamento de patologias e/ou infecções respiratórias e no aperfeiçoamento da funcionalidade intestinal
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BR0111210A (pt) Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias
BR112023001143A2 (pt) Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo
Wilde et al. Inhibition of p38 mitogen-activated protein kinase signaling reduces fibrosis and lipid accumulation after rotator cuff repair
Bernardes et al. In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
Ditsios et al. Bone loss following tendon laceration, repair and passive mobilization
Lavinya et al. Efficacy of CoenzymeQ10 in inhibiting monosodium urate crystal-induced inflammation in rats
Osuntokun et al. Assessment of the biomarkers of hepatotoxicity following carbamazepine, levetiracetam, and carbamazepine-levetiracetam adjunctive treatment in male Wistar rats
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
JP2005523281A (ja) アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ
BRPI0607801A2 (pt) método para tratar seletivamente distúrbio mediado pela cox-2 através da administração de gama-tocoferol
Doyle et al. Effects of sodium hyaluronate and methylprednisolone acetate on proteoglycan synthesis in equine articular cartilage explants
BR112022018794A2 (pt) Método para melhorar a estabilidade de uma composição farmacêutica compreendendo um fármaco de alta penetração e a composição farmacêutica obtida dele
Jackson et al. Splint bone fractures in the horse: a retrospective study 1992–2001
Sedky et al. Regulatory effect of Balanites aegyptiaca ethanol extract on oxidant/antioxidant status, inflammatory cytokines, and cell apoptosis gene expression in goat abomasum experimentally infected with Haemonchus Contortus
BRPI0607851A2 (pt) compostos e usos dos mesmos
BR112012030117A2 (pt) pluralidade de composições, uso da mesma e método para a prevenção ou tratamento de doença cardiovascular, diabetes do tipo 2, inflamação, diarréia e saúde óssea
Singh et al. Intra-arterial injection of Mesobuthus tamulus venom elicits cardiorespiratory reflexes involving perivascular afferents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.